A Phase III Double Blind Randomised Placebo Controlled Study to Assess thefficacy and Safety of Selumetinib AZD6244 ARRY 142886 Hyd Sulfate in Combination with Docetaxel in Patients Receiving Second Line Treatment for KRAS Mutation Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIB IV